Montreal Heart Institute
5000 Belanger Street
Montreal
Quebec
H1T 1C8
Canada
Tel: 514-376-3330
Website: http://www.icm-mhi.org/
45 articles about Montreal Heart Institute
-
The Montreal Heart Institute Welcomes FDA Approval of Colchicine for the Treatment of Cardiovascular Diseases
6/23/2023
The Montreal Heart Institute (MHI) welcomes the approval by the United States Food and Drug Administration (FDA) of colchicine for cardiovascular prevention.
-
Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study
8/27/2021
People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events.
-
Results of the COLCORONA study published in The Lancet Respiratory Medicine
5/28/2021
Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications
-
Results of the COLCORONA study published in The Lancet Respiratory MedicineColchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications
5/27/2021
The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.
-
BRAIN-AF Study Receives Canadian Institutes of Health Research GrantThis money will allow for the expansion of remote recruitment of participants for this research that aims to treat the heart and help the brain
3/16/2021
The Montreal Heart Institute (MHI) announces that the BRAIN-AF study has received a $1.4 million grant from the Canadian Institutes of Health Research.
-
Colchicine reduces the risk of COVID-19-related complicationsPositive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients
1/23/2021
The Montreal Heart Institute announced that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19.
-
New data supports development of colchicine for the prevention of acute respiratory distress syndrome
12/3/2020
The Montreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models
-
Colchicine shows promise as a treatment for at-home COVID-19 patients -- Recruitment of participants in the COLCORONA phase 3 study likely to end in 2020
11/28/2020
The Montreal Heart Institute announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee, following a second interim analysis.
-
Pharmascience Inc. reiterates its support to the Montreal Heart Institute's colchicine repurposing research studies in cardiovascular medicine and COVID-19
8/31/2020
The Montreal Heart Institute (MHI) released earlier today two more research publications confirming the benefits of low dose (0,5mg daily) colchicine in preventing the risks of ischemic cardiovascular events in patients having undergone myocardial infarction (MI). These were sub-analyses of the landmark COLCOT I trial carried out last year
-
Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack
8/29/2020
Colchicine also being evaluated as a treatment to prevent complications and death related to severe cases of COVID-19 by the Montreal Heart Institute
-
Nearly Half of Americans Surveyed Willing to Consider Participating in Generic Drug Trials for COVID-19 Treatments Despite Testing Notification Delays up to Six Days
8/23/2020
While Nearly 80% Surveyed are Seeing Media Reports on the Usage of Hydroxychloroquine by Public Officials, Very Few Are Seeing Information on Available Clinical Trials Like the COLCORONA Trial
-
Montreal Heart Institute announces COLCORONA trial in patients with COVID-19 passes futility test in interim analysisColchicine, a common drug to treat gout, is being evaluated as a potential treatment in the fight against coronavirus
6/27/2020
Montreal Heart Institute announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee, following a futility analysis.
-
FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke
6/16/2020
The Montreal Heart Institute (MHI) and Thermedical ® , a developer of thermal-ablation systems to treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminate over 98% of
-
FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of StrokeMontreal Heart Institute First to use New Degassed Saline During Innovative Cardiac Ablation Procedure
6/16/2020
The Montreal Heart Institute (MHI) and Thermedical ® , a developer of thermal-ablation systems to treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminate over 98% of the air bubbles that can lead to stroke. Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedical’s
-
Montreal Heart Institute Colcorona Study receives grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation to investigate cheap, readily available drug
5/12/2020
Clinical study evaluating colchicine as a potential treatment to reduce inflammatory conditions seen in patients with COVID-19
-
National Institutes of Health (NIH) helps fund ColCorona COVID-19 clinical study
5/5/2020
Study examines if colchicine, a common gout medication, can reduce complications associated with COVID-19, slow disease progression, and save patient lives
-
Contactless COVID-19 Clinical Study Starts in OntarioCOLCORONA investigating whether colchicine can reduce severe inflammatory conditions associated with COVID-19, slow disease progression, and save patient lives
4/30/2020
The Montreal Heart Institute Research Center has extended its COLCORONA COVID-19 clinical trial to a third Canadian province being Ontario.
-
Vancouver Infectious Diseases Centre joins Montreal Heart Institute to evaluate potential treatment against COVID-19
4/8/2020
COLCORONA trial to examine whether colchicine can reduce complications associated with COVID-19, slow disease progression, and save patient lives
-
New clinical trial for treatment of COVID-19 positive patients to start at NYU Grossman School of Medicine in partnership with Montreal Heart Institute
4/7/2020
COLCORONA trial to examine whether colchicine can reduce complications associated with COVID-19, slow disease progression, and save patient lives
-
Message of public interest: Clinical study for people infected with COVID-19Looking for 6000 participants
3/27/2020
People infected with COVID-19 diagnosed in the last 24 hours can call 1-877-536-6837 to participate in clinical research aimed to stop the progression of the disease.